Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I single ascending dose pharmacokinetic study of MAT-2501 in healthy volunteers

Next Previous
X
Search
Trial Profile

A phase I single ascending dose pharmacokinetic study of MAT-2501 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary)
  • Indications Gram-negative infections; Nontuberculous mycobacterium infections
  • Focus Pharmacokinetics

    • Most Recent Events

    • 21 Oct 2021 According to a Matinas BioPharma media release, the first patient has been dosed in this study. The Company expects to complete enrollment of the Phase 1 SAD study in the first quarter of 2022, with data anticipated during the second quarter of 2022.
    • 21 Oct 2021 Status changed from planning to recruiting, according to a Matinas BioPharma media release.
    • 10 Aug 2021 According to a Matinas BioPharma media release, the company expects to initiate this study in the fourth quarter of 2021. The initiation of this study follows positive feedback received from the FDA on the ongoing preclinical toxicology and efficacy studies of MAT2501 conducted in collaboration with the Cystic Fibrosis Foundation (CFF).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top